Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes
JNCI Cancer Spectrum · 2024
DOI: 10.1093/jncics/pkae095 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2024. Verfasst von Nikhil Grandhi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Research Service, St Louis VA Medical Center, St Louis, MO, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Disease Progression, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS, Siteman Cancer Center.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
In patients with diabetes and monoclonal gammopathy of uncertain significance (MGUS), the impact of glucagon-like peptide-1 (GLP-1) receptor agonists on the natural history of MGUS is unknown. We aimed to assess the association of GLP-1 receptor agonist use in the progression of MGUS to multiple myeloma in patients with diabetes.
Methods
This is a population-based cohort study of veterans diagnosed with MGUS from 2006 to 2021 with a prior diagnosis of diabetes. A validated natural language processing algorithm was used to confirm MGUS and progression to multiple myeloma. We performed 1:2 matching for individuals with and without GLP-1 receptor agonist exposure. The Gray test was performed to detect the difference in cumulative incidence functions for progression by GLP-1 receptor agonist use status. The association between time-varying GLP-1 receptor agonist use and progression was estimated through multivariable-adjusted hazard ratio using a stratified Fine-Gray distribution hazard model, with death as a competing event and stratum for the matched patient triad.
Results
Our matched cohort included 1097 individuals with MGUS who had ever used GLP-1 receptor agonists and the matched 2194 patients who had never used GLP-1 receptor agonists. Overall, 2.6% of individuals progressed in the GLP-1 receptor agonist ever use group compared with 5.0% in the GLP-1 receptor agonist never use group. Cumulative incidence functions were statistically significantly different between the exposed and unexposed groups (P = .02). GLP-1 receptor agonist use vs no use was associated with decreased progression to multiple myeloma (hazard ratio = 0.45, 95% confidence interval = 0.22 to 0.93, P = .03).
Conclusions
For patients with diabetes and MGUS, GLP-1 receptor agonist use is associated with a 55% reduction in risk of progression from MGUS to multiple myeloma compared with no use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research Service, St Louis VA Medical Center, St Louis, MO, USA.
- Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
- City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
- Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, MO, USA.
- Department of Medicine, Saint Louis University School of Medicine, St Louis, MO, USA.
- Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
ORCID-Profile: Nikhil Grandhi, Lawrence Liu, Mei Wang, Martin Schoen, Graham A Colditz, Kenneth R Carson, Su-Hsin Chang
Förderung
- NCI NIH HHS
- NIH HHS
- Siteman Cancer Center
- National Institutes of Health
Zitieren
APA
Grandhi, N., Liu, L., Wang, M., Thomas, T., Schoen, M., Sanfilippo, K., Gao, F., Colditz, G. A., Carson, K. R., Janakiram, M., & Chang, S. H. (2024). Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkae095
Vancouver
Grandhi N, Liu L, Wang M, Thomas T, Schoen M, Sanfilippo K, et al. Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes. JNCI Cancer Spectrum. 2024. doi:10.1093/jncics/pkae095
BibTeX
@article{Grandhi2024,
author = {Grandhi, Nikhil and Liu, Lawrence and Wang, Mei and Thomas, Theodore and Schoen, Martin and Sanfilippo, Kristen and Gao, Feng and Colditz, Graham A and Carson, Kenneth R and Janakiram, Murali and Chang, Su-Hsin},
title = {Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes},
journal = {JNCI Cancer Spectrum},
year = {2024},
doi = {10.1093/jncics/pkae095}
}
EUVIMED